Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. and certain officers for alleged violations of federal securities laws during the Class Period from August 3, 2023, to December 26, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for investors who purchased Ultragenyx securities during the specified Class Period [2]. - The Complaint alleges that the defendants made false and misleading statements regarding the effects of setrusumab on patients with Osteogenesis Imperfecta and downplayed the risks associated with the Phase III Orbit study [3]. - It is claimed that Ultragenyx's optimism regarding the Phase III study results was unfounded, as the Phase II results lacked a placebo control group, raising concerns about the validity of the reported reduction in annualized fracture rate [3]. Group 2: Next Steps for Investors - Investors affected by the situation have until April 6, 2026, to request to be appointed as lead plaintiff in the class action [4]. - Participation in any recovery does not require serving as lead plaintiff [4]. Group 3: Legal Representation - Bronstein, Gewirtz & Grossman LLC operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and fees if successful in the lawsuit [5]. - The firm has a strong track record, having recovered hundreds of millions of dollars for investors in similar cases [6].

Core Viewpoint - The Ultragenyx Pharmaceutical Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives made misleading statements regarding the efficacy of their drug setrusumab during clinical trials [1][3]. Group 1: Class Action Details - The class action lawsuit is titled Bailey v. Ultragenyx Pharmaceutical Inc. and covers purchasers of Ultragenyx common stock from August 3, 2023, to December 26, 2025 [1]. - Investors have until April 6, 2025, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit alleges that Ultragenyx misrepresented the reliability of information regarding the effects of setrusumab on Osteogenesis Imperfecta patients and downplayed the risks associated with the Phase III Orbit study [3]. Group 2: Study Results and Stock Impact - On July 9, 2025, Ultragenyx disclosed that the Phase III Orbit study did not achieve statistical significance for its second interim analysis, leading to a stock price drop of over 25% [4]. - On December 29, 2025, the company announced that both the Phase III Orbit and Cosmic studies failed to meet primary endpoints, resulting in a further stock price decline of more than 42% [5]. Group 3: Legal Process and Firm Background - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Ultragenyx stock during the class period to seek lead plaintiff status, representing the interests of the class [6]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized as a leading firm in securities fraud litigation, having recovered over $916 million for investors in 2025 alone [7].

Core Viewpoint - ClaimsFiler is reminding investors about the deadline for filing lead plaintiff applications in a securities class action lawsuit against Ultragenyx Pharmaceutical Inc. [1] Group 1: Lawsuit Details - The deadline for filing lead plaintiff applications is April 6, 2026 [1] - The class action lawsuit pertains to investors who purchased or acquired shares of Ultragenyx between August 3, 2023, and December 26, 2025 [1] - The lawsuit is currently pending in the United States District Court for the Southern District of New York [1]

Core Insights - Ultragenyx allegedly misled investors regarding the potential success of setrusumab's Phase 3 study in reducing fracture rates [1] Company Summary - The company is facing allegations of misleading investors about the efficacy of setrusumab in its clinical trials [1]

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. on behalf of investors who purchased its common stock during the specified Class Period from August 3, 2023, to December 26, 2025 [1][2]. Company Overview - Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on acquiring and developing novel products for the treatment of rare genetic diseases, headquartered in Novato, California [2]. Lawsuit Details - The lawsuit claims that throughout the Class Period, Ultragenyx made overwhelmingly positive statements regarding the ORBIT and COSMIC Phase 3 clinical trials for setrusumab, intended to treat Osteogenesis Imperfecta [3]. - On December 29, 2025, Ultragenyx disclosed that neither clinical trial achieved its primary endpoint of reducing the annualized clinical fracture rate, resulting in a significant share price drop of over 42%, from $34.19 per share on December 26, 2025, to $19.72 per share on December 29, 2025 [4].

Core Viewpoint - The complaint against Ultragenyx alleges violations of federal securities laws due to misleading statements regarding the efficacy of setrusumab in treating Osteogenesis Imperfecta, particularly concerning the Phase III Orbit study results and the associated risks [2]. Group 1: Allegations and Misleading Information - The complaint claims that Ultragenyx and its executives created a false impression of having reliable information about setrusumab's effects on patients with Osteogenesis Imperfecta [2]. - It is alleged that Ultragenyx downplayed the risk that patients in the Phase III Orbit study would not achieve a statistically significant reduction in annualized fracture rate, which is critical for the study's interim analysis [2]. - The optimism expressed by Ultragenyx regarding the Phase III Orbit study's results is said to be misplaced, as the company failed to adequately disclose the risks associated with relying on Phase II results that lacked a placebo control group [2]. Group 2: Legal Proceedings and Class Action - The lead plaintiff in the class action is the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [3]. - Any member of the putative class has the option to move the court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [3]. Group 3: Whistleblower Encouragement - The law firm Faruqi & Faruqi encourages individuals with information regarding Ultragenyx's conduct, including whistleblowers and former employees, to come forward [4].

Core Viewpoint - Ultragenyx Pharmaceutical Inc. is facing a lawsuit for alleged violations of securities laws, which may impact its financial standing and investor confidence [1] Group 1 - The lawsuit has been initiated by the DJS Law Group, indicating potential legal challenges for the company [1] - The allegations pertain to securities law violations, which could lead to significant financial repercussions for Ultragenyx [1] - Investors are encouraged to discuss their rights in light of the ongoing legal situation [1]

Core Viewpoint - A class action has been filed against Ultragenyx Pharmaceutical Inc. for allegedly misleading investors regarding the efficacy of setrusumab in clinical studies, leading to significant stock price decline after the announcement of study failures [1][4]. Group 1: Allegations and Misleading Information - Robbins LLP is investigating allegations that Ultragenyx misled investors about the expected results of its Phase III Orbit and Cosmic Studies for setrusumab, claiming it would reduce fracture rates in Osteogenesis Imperfecta patients [2]. - The complaint asserts that Ultragenyx provided overly positive statements while concealing material adverse facts about setrusumab's potential and the risks associated with the study protocols, particularly that increased bone density did not correlate with reduced fracture rates [3]. Group 2: Study Results and Stock Impact - On December 29, 2025, Ultragenyx announced that its Phase III studies did not achieve statistical significance in reducing annualized clinical fracture rates compared to placebo or bisphosphonates, attributing the failure to a low fracture rate in the placebo group [4]. - Following this announcement, Ultragenyx's stock price plummeted from $34.19 per share on December 26, 2025, to $19.72 per share on December 29, 2025, marking a decline of approximately 42.32% in one day [4].

Core Viewpoint - A class action securities lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for alleged securities fraud affecting investors between August 3, 2023, and December 26, 2025 [1] Group 1 - The lawsuit is initiated by Kahn Swick & Foti, LLC and its partner, former Attorney General of Louisiana, Charles C. Foti, Jr. [1] - The action seeks to recover losses for investors adversely affected by the alleged fraud [1]

Core Viewpoint - RARE investors are presented with an opportunity to lead a securities fraud lawsuit against Ultragenyx Pharmaceutical Inc. in collaboration with the Schall Law Firm [1] Group 1 - The lawsuit is focused on allegations of securities fraud involving Ultragenyx Pharmaceutical Inc. [1] - The Schall Law Firm is actively seeking investors who have suffered losses to participate in the lawsuit [1] - This legal action may provide a platform for investors to seek restitution for their financial losses related to the company's alleged misconduct [1]